KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Other Operating Expenses (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Other Operating Expenses for 7 consecutive years, with $119.2 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 4.71% to $119.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $474.4 million through Dec 2025, down 2.16% year-over-year, with the annual reading at $470.2 million for FY2025, 2.12% down from the prior year.
  • Other Operating Expenses hit $119.2 million in Q4 2025 for GoodRx Holdings, up from $118.4 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $152.5 million in Q4 2023 to a low of -$47.9 million in Q4 2021.
  • Historically, Other Operating Expenses has averaged $73.9 million across 5 years, with a median of $114.1 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: crashed 154.05% in 2021 and later surged 7834.74% in 2023.
  • Year by year, Other Operating Expenses stood at -$47.9 million in 2021, then soared by 95.88% to -$2.0 million in 2022, then soared by 7834.74% to $152.5 million in 2023, then dropped by 17.97% to $125.1 million in 2024, then decreased by 4.71% to $119.2 million in 2025.
  • Business Quant data shows Other Operating Expenses for GDRX at $119.2 million in Q4 2025, $118.4 million in Q3 2025, and $117.9 million in Q2 2025.